Current role
Biotechnology · Healthcare
CEO, Board Member
2024-06-14–present
Joseph E. Payne
Equibles does not estimate personal net worth.
Get an email with a short summary when Arcturus Therapeutics Holdings Inc. publishes a filing, an earnings call transcript or a press release.
Get ARCT alertsAbout Joseph E. Payne
Joseph E. Payne is recorded as Board Member at Arcturus Therapeutics Holdings Inc. (ARCT) since June 14, 2024 and CEO at Arcturus Therapeutics Holdings Inc. (ARCT). The newest filing on record that lists Joseph E. Payne as CEO and Board Member at Arcturus Therapeutics Holdings Inc. (ARCT) is dated April 24, 2026. Arcturus Therapeutics Holdings Inc. reported in an 8-K filed June 14, 2024 that Joseph E. Payne was appointed Director, effective June 14, 2024. The proxy statement of Arcturus Therapeutics Holdings Inc. reports total compensation of $1,691,000 for Joseph E. Payne in fiscal 2025, including a base salary of $750,000. Disclosed compensation is on record for 8 fiscal years. Arcturus Therapeutics Holdings Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcturus Therapeutics Holdings Inc. includes Joseph Payne (CEO and Board Member), Andy Sassine (CFO and Board Member), Dennis Mulroy (CFO) and 7 others.
“Each of the eight nominees was elected to the Board, each to hold office until the Company's 2025 annual meeting of stockholders and until their respective successors are elected and qualified.”
Affiliation history
-
Current
2024-06-14–present
Last confirmed April 24, 2026
-
Current
Start not stated–present
Last confirmed April 24, 2026
Company network
Leadership on record at Arcturus Therapeutics Holdings Inc.
- Joseph Payne CEO, Board Member
- Andy Sassine CFO, Board Member
- Dennis Mulroy CFO
- Joe Roberts CFO, Chief Accounting Officer
- Padmanabh Chivukula COO
- Dr. Edward W. Holmes Board Member
- Dr. Jing L. Marantz Board Member
- Dr. Jing Marantz Board Member
- Dr. John H. Markels Board Member
- Dr. Magda Marquet Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Arcturus Therapeutics Holdings Inc. (ARCT) | President and Chief Executive Officer, Director | $750,000 | $1,691,000 |
| 2024 | Arcturus Therapeutics Holdings Inc. (ARCT) | President and Chief Executive Officer, Director | $695,000 | $3,697,000 |
| 2023 | Arcturus Therapeutics Holdings Inc. (ARCT) | President and Chief Executive Officer, Director | $698,000 | $4,892,500 |
| 2022 | Arcturus Therapeutics Holdings Inc. (ARCT) | President and Chief Executive Officer, Director | $630,000 | $5,594,000 |
| 2021 | Arcturus Therapeutics Holdings Inc. (ARCT) | President and Chief Executive Officer, Director | $600,000 | $960,000 |
| 2020 | Arcturus Therapeutics Holdings Inc. (ARCT) | President and Chief Executive Officer, Director | $500,000 | $12,861,500 |
| 2019 | Arcturus Therapeutics Holdings Inc. (ARCT) | President and Chief Executive Officer, Director | $450,000 | $1,165,818 |
| 2018 | Arcturus Therapeutics Holdings Inc. (ARCT) | President and Chief Executive Officer, Director | $425,000 | $2,687,044 |